{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:02:02Z","timestamp":1790218922188,"version":"4.1.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychiatric Disease and Treatment"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.2147\/nedt.2006.2.2.127","type":"journal-article","created":{"date-parts":[[2006,9,5]],"date-time":"2006-09-05T11:13:34Z","timestamp":1157454814000},"page":"127-138","source":"Crossref","is-referenced-by-count":13,"title":["Risperidone in the treatment of bipolar mania"],"prefix":"10.2147","volume":"2","author":[{"given":"Martha","family":"Sajatovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Subramoniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Madhusoodanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"p_1_423","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association; America Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","journal-title":"Diabetes Care"},{"key":"p_2_424","unstructured":"[APA] American Psychiatric Association. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Washington, DC: APA."},{"key":"p_3_425","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.yic.0000138821.85744.20","volume":"19","author":"Bahk WM","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"p_4_426","doi-asserted-by":"crossref","unstructured":"Biederman J. 2003. Open-label study of risperidone in children with bipolar disorder. Presented at the 16\n                      th\n                      annual meeting of the European Neuropsychopharmacology Congress [abstract]. 2003 September 20-24; Prague, Czech Republic. P.2.079.","DOI":"10.1016\/S0924-977X(03)92032-3"},{"key":"p_5_427","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v65n0518","volume":"65","author":"Bowden CL","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"p_6_428","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"Calabrese JR","year":"2005","journal-title":"Am J Psychiatry"},{"key":"p_7_429","unstructured":"[FDA] Food and Drug Administration Center for Drug Evaluation and Research. 2005. Public Health Advisory. April 11."},{"key":"p_8_430","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00023210-200519050-00005","volume":"19","author":"Fenton C","year":"2005","journal-title":"CNS Drugs"},{"key":"p_9_431","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199908000-00011"},{"key":"p_10_432","unstructured":"Fuller MA, Sajatovic M. 2005. Drug information handbook for psychiatry. Cleveland, OH: Lexi-Comp."},{"key":"p_11_433","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/10401230490453103","volume":"16","author":"Ghaemi SN","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"p_12_434","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4088\/JCP.v66n0809","volume":"66","author":"Gopal S","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"p_13_435","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4088\/JCP.v61n0907","volume":"61","author":"Guille C","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"p_14_436","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","volume":"161","author":"Hirschfeld RM","year":"2004","journal-title":"Am J Psychiatry"},{"key":"p_15_437","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4088\/JCP.v64n0111","volume":"64","author":"Hirschfeld RM","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"p_16_438","unstructured":"Janssen Pharmaceuticals 2003a. Risperdal\n                      R\n                      (Consta\n                      R\n                      ) product information 2003. Titusville, NJ, USA: Janssen."},{"key":"p_17_439","unstructured":"Janssen Pharmaceuticals 2003b. Risperidone (Risperdal\n                      R\n                      ) product information. Titusville, NJ, USA: Janssen."},{"key":"p_18_440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","volume":"462","author":"Kalkman HO","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"p_19_441","unstructured":"Keck PE, Perlis RH, Otto MW, etal 2004. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgrad Med Special Report :1-120."},{"key":"p_20_442","unstructured":"Khanna S, Vieta E, Lyons B, etal 2003. Risperidone monotherapy in acute bipolar mania [poster]. Fifth International conference on bipolar disorder (ICBD). 2003; Pittsburgh, USA."},{"key":"p_21_443","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.187.3.229","volume":"187","author":"Khanna S","year":"2005","journal-title":"Br J Psychiatry"},{"key":"p_22_444","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00158.x"},{"key":"p_23_445","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200503000-00006"},{"key":"p_24_446","first-page":"5","volume":"55","author":"Leyson JE","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"p_25_447","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00004850-200103000-00005","volume":"16","author":"Licht RW","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"p_26_448","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.2.290"},{"key":"p_27_449","first-page":"218","volume":"11","author":"McIntyre RS","year":"2004","journal-title":"Can J Clin Pharmacol"},{"key":"p_28_450","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"Newcomer JW","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"p_29_451","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00004850-200206001-00002","volume":"17","author":"Pania L","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"p_30_452","unstructured":"Petrie W, 2004. Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who are receiving a primary thymoleptic agent. American Psychiatric Association 157\n                      th\n                      Annual Meeting. 2004 May 1-6; New York, USA."},{"key":"p_31_453","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1993.01820140007001","volume":"50","author":"Regier DA","year":"1993","journal-title":"Arch Gen Psychiatr"},{"key":"p_32_454","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"p_33_455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2004.00409.x","volume":"422","author":"Sachs GS.","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"p_34_456","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1176\/appi.ps.55.9.1014","volume":"55","author":"Sajatovic M","year":"2004","journal-title":"Psychiatr Serv"},{"key":"p_35_457","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14737175.5.2.177","volume":"5","author":"Sajatovic M","year":"2005","journal-title":"Expert Rev Neurother"},{"key":"p_36_458","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2190\/NY2L-6YF4-B1DA-W6DX","volume":"26","author":"Sajatovic M","year":"1996","journal-title":"Int J Psychiatry Med"},{"key":"p_37_459","first-page":"176","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"p_38_460","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.4088\/JCP.v65n1218","volume":"65","author":"Shelton RC","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"p_39_461","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","volume":"15","author":"Smulevich AB","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"p_40_462","unstructured":"Stahl SM, Shelton RC, 2001. Risperidone with and without paroxetine compared with paroxetine alone for bipolar depression. 41\n                      st\n                      Annual meeting of the American College of Neuropsychopharmacology (ACNP). 2001; Hawaii, USA."},{"key":"p_41_463","doi-asserted-by":"publisher","DOI":"10.1002\/hup.556"},{"key":"p_42_464","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4088\/JCP.v62n1011","volume":"62","author":"Vieta E","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"p_43_465","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0165-0327(01)00481-5","volume":"72","author":"Vieta E","year":"2002","journal-title":"J Affect Disord"},{"key":"p_44_466","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","volume":"182","author":"Yatham LN","year":"2003","journal-title":"Br J Psychiatry"}],"container-title":["Neuropsychiatric Disease and Treatment"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:30:59Z","timestamp":1790217059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/risperidone-in-the-treatment-of-bipolar-mania-peer-reviewed-fulltext-article-NDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.2147\/nedt.2006.2.2.127"],"URL":"https:\/\/doi.org\/10.2147\/nedt.2006.2.2.127","relation":{},"ISSN":["1176-6328"],"issn-type":[{"value":"1176-6328","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}